BACKGROUND AND PURPOSE: Investigation of the use of TomoTherapy and TomoDirect versus conventional radiotherapy for the treatment of post-operative breast carcinoma. This study concentrates on the evaluation of the planning protocol for the TomoTherapy and TomoDirect TPS, dose verification and the implementation of in vivo dosimetry. MATERIALS AND METHODS: Eight patients with different breast cancer indications (left/right tumor, axillary nodes involvement (N+)/no nodes (N0), tumorectomy/mastectomy) were enrolled. TomoTherapy, TomoDirect and conventional plans were generated for prone and supine positions leading to six or seven plans per patient. Dose prescription was 42Gy in 15 fractions over 3weeks. Dose verification of a TomoTherapy plan is performed using TLDs and EDR2 film inside a home-made wax breast phantom fixed on a rando-alderson phantom. In vivo dosimetry was performed with TLDs. RESULTS: It is possible to create clinically acceptable plans with TomoTherapy and TomoDirect. TLD calibration protocol with a water equivalent phantom is accurate. TLD verification with the phantom shows measured over calculated ratios within 2.2% (PTV). An overresponse of the TLDs was observed in the low dose regions (<0.1Gy). The film measurements show good agreement for high and low dose regions inside the phantom. A sharp gradient can be created to the thoracic wall. In vivo dosimetry with TLDs was clinically feasible. CONCLUSIONS: The TomoTherapy and TomoDirect modalities can deliver dose distributions which the radiotherapist judges to be equal to or better than conventional treatment of breast carcinoma according to the organ to be protected.
BACKGROUND AND PURPOSE: Investigation of the use of TomoTherapy and TomoDirect versus conventional radiotherapy for the treatment of post-operative breast carcinoma. This study concentrates on the evaluation of the planning protocol for the TomoTherapy and TomoDirect TPS, dose verification and the implementation of in vivo dosimetry. MATERIALS AND METHODS: Eight patients with different breast cancer indications (left/right tumor, axillary nodes involvement (N+)/no nodes (N0), tumorectomy/mastectomy) were enrolled. TomoTherapy, TomoDirect and conventional plans were generated for prone and supine positions leading to six or seven plans per patient. Dose prescription was 42Gy in 15 fractions over 3weeks. Dose verification of a TomoTherapy plan is performed using TLDs and EDR2 film inside a home-made wax breast phantom fixed on a rando-alderson phantom. In vivo dosimetry was performed with TLDs. RESULTS: It is possible to create clinically acceptable plans with TomoTherapy and TomoDirect. TLD calibration protocol with a water equivalent phantom is accurate. TLD verification with the phantom shows measured over calculated ratios within 2.2% (PTV). An overresponse of the TLDs was observed in the low dose regions (<0.1Gy). The film measurements show good agreement for high and low dose regions inside the phantom. A sharp gradient can be created to the thoracic wall. In vivo dosimetry with TLDs was clinically feasible. CONCLUSIONS: The TomoTherapy and TomoDirect modalities can deliver dose distributions which the radiotherapist judges to be equal to or better than conventional treatment of breast carcinoma according to the organ to be protected.
Authors: Hilde Van Parijs; Geertje Miedema; Vincent Vinh-Hung; Sylvia Verbanck; Nele Adriaenssens; Dirk Kerkhove; Truus Reynders; Daniel Schuermans; Katrien Leysen; Shane Hanon; Guy Van Camp; Walter Vincken; Guy Storme; Dirk Verellen; Mark De Ridder Journal: Radiat Oncol Date: 2012-06-01 Impact factor: 3.481
Authors: Yat Tsang; Laura Ciurlionis; Anna M Kirby; Imogen Locke; Karen Venables; John R Yarnold; Jenny Titley; Judith Bliss; Charlotte E Coles Journal: Br J Radiol Date: 2015-10-22 Impact factor: 3.039
Authors: Nele Adriaenssens; Vincent Vinh-Hung; Geertje Miedema; Harijati Versmessen; Jan Lamote; Marian Vanhoeij; Pierre Lievens; Hilde van Parijs; Guy Storme; Mia Voordeckers; Mark De Ridder Journal: Breast Cancer (Auckl) Date: 2012-07-30